We recently published a list of Jim Cramer Reveals Trump’s Potential Secret Weapon In China Trade Talks & Discusses These 10 Stocks. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer discussed the impacts that tariffs have had on businesses. He shared that firms are scrambling to diversify their supply chains from China as higher costs affect business margins. Using the example of the firm known for making Monopoly and Nerf, Cramer commented: “Well I mean look everybody’s scrambling, I know that. . .[toy company’s] scrambling everywhere to be able to make it so that a nine dollar toy doesn’t cost 19. And I think that our companies are, often, not given the credit that they deserve to be able to get things to move around, pull their weight, do things overseas, David, it’s not like they’re the only ones, China, that can make this stuff. Cause the stuff is not like, it’s not like making a Grace Blackwell GB200 NVIDIA chip.” One material that’s caught Cramer’s attention is ethane. He believes that ethane’s role in the plastics supply chain and the fact that China can’t make it can enable the material to play a key role in President Trump’s trade talks. Cramer commented: “We have to focus on this ethylene, because it’s the one thing that they’re panicked on in China. They’re not panicked on copper, they’re panicked that they’re not getting ethane, which makes ethylene, which makes plastic. Because boy do they ever make make plastic.” In fact, Cramer went as far as to ‘advise’ the President and his team to leverage US ethane production against China: “But the building block of all that stuff is Louisiana, ethane. If the President and Navarros and these trade guys were to say, you know what guys, we saw that you wouldn’t tariff ethane, cause you need it so bad, we’re done, we’re gonna ship it to Korea. Then see what happens. That’s what they should do. That’s like, free advice there.” As for the car industry, Cramer believes that Trump’s advisor Peter Navarro won’t be satisfied even if some car companies build their assembly plans in America. “Peter Navarro would say over and over, we need the engines made we don’t want the assembly,” he believes. Our Methodology To make our list of the stocks that Jim Cramer talked about, we listed down the stocks he mentioned during CNBC’s Squawk on the Street aired on May 1st. For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). Story Continues Jim Cramer on CVS Health (CVS): "David Joyner’s Stunning Turnaround Continues" A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. CVS Health Corporation (NYSE:CVS) Number of Hedge Fund Holders In Q4 2024: 74 CVS Health Corporation (NYSE:CVS) is one of the biggest pharmaceutical chains in America. Its shares have also performed well this year, as they are up by 54.5% year-to-date. CVS Health Corporation (NYSE:CVS) has benefited from troubles at its peer Walgreens and investors’ tendency to flee into safer stocks during times of turmoil, such as the recent tariff-related uncertainties. Here’s what Cramer said about CVS Health Corporation (NYSE:CVS): “. . .and how about what David Joyner’s done at CVS? I mean, it’s extraordinary. He’s turning that thing around. Who would have thought that?” Overall, CVS ranks 6th on our list of stocks that Jim Cramer recently discussed. While we acknowledge the potential of CVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CVS but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Jim Cramer on CVS Health Corporation (CVS): ‘David Joyner’s Stunning Turnaround Continues’
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...